Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 297

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 297
---
 |
| Lease liability                          |     |       |  53,142 |     |        |  36,726 |     |           | 16,416 |
|                                          |     | $     | 628,160 |     | $      | 611,744 |     | $         | 16,416 |

F-56 CLEARMIND MEDICINE INC. Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended July 31, 2025 and 2024 (Expressed in United States Dollars) (Unaudited)

| 11. | Capital Management |

The Company manages its capital to
maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders. The capital
structure of the Company consists of cash and equity comprised of issued share capital and share premium, warrants and share-based payment
reserve.

The Company manages its capital structure
and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board, will balance its overall capital
structure through new share issuances or by undertaking other activities as deemed appropriate under the specific circumstances.

The Company is not subject to externally
imposed capital requirements and the Company’s overall strategy with respect to capital risk management remains unchanged from the
nine months ended July 31, 2025.

| 12. | Segmented Information |

As of July 31, 2025, the Company has
operating segment, being the research and development of novel psychedelic medicine, which takes place primarily in Israel.

| 13. | Commitments |

| b. | On March 19, 2024, the Company entered into a License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, which provides to the Company with an exclusive, perpetual, worldwide and sublicensable license to use the Yissum’s patent titled “Psychedelic compounds, methods of their preparation and uses thereof” to further develop, manufacture, and commercialize innovative compounds targeted at treating post-traumatic stress disorder and other health conditions (the “Yissum PTSD License Agreement”). According to the Yissum PTSD License Agreement, the Company is required to pay Yissum annual maintenance fees ranging from $25,000 to $50,000 beginning on the fifth anniversary of the effective date of the Yissum PSTD License Agreement, and royalties at the rate of 3.0% of net sales, as well as certain fees in